This trial is testing a new drug (FEP-ZID) to see if it is as effective as another drug (meropenem) in treating adults with cUTI or AP. 528 adults with cUTI or AP will be enrolled and remain hospitalized during treatment, which will last 7-10 days.
2 Primary · 7 Secondary · Reporting Duration: On Days 1 and 3 of dosing prior to infusion, within 15 minutes after the end of infusion, and at 3 timepoints up to 7 hours hours post infusion
528 Total Participants · 2 Treatment Groups
Primary Treatment: Cefepime-zidebactam (FEP-ZID) · No Placebo Group · Phase 3
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: